This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kereiakes, D. J. Search for Related Content PubMed PubMed Citation Articles by Kereiakes, D. J. Related Collections Restenosis Catheter-based coronary interventions: stents

(Circulation. 2003;107:3012.)
© 2003 American Heart Association, Inc.

Mini-Review: Expert Opinions

Hippocrates Revisited

The Evidence for Drug-Eluting Stents

Dean J. Kereiakes, MD

From the Carl and Edyth Lindner Center for Research and Education, Ohio Heart Health Center, Cincinnati, Ohio.

Reprint requests to Dean J. Kereiakes, MD, The Lindner Center for Research and Education, 2123 Auburn Ave, Suite 424, Cincinnati, OH 45219. E-mail lindner@fuse.net

An extract of the first 250 words of the full text is provided, because this article has no abstract.

	Introduction

 

As to diseases, make a habit of two things—to help, or at least do no harm.

— —Hippocrates, in The Epidemics

Evidence-based medicine provides proof of efficacy ("to help") and defines the risk-benefit relationship ("do no harm") for specific therapeutic intervention. Guidelines provide an algorithm by which evidence-based medicine is incorporated into clinical practice. The cornerstone of evidence-based medicine is the randomized controlled clinical trial. On the basis of carefully constructed and well-executed randomized trials, the US Food and Drug Administration (FDA) has recently approved and released the Cypher sirolimus-eluting Bx VELOCITY coronary stent (Cordis, a Johnson and Johnson Company). Other drug-eluting coronary stent prostheses are currently under investigation. Because of its cost, the clinical benefit demonstrated for Cypher (versus uncoated Bx VELOCITY stents) has been scrutinized. The present cost of Cypher ($3195) is at least 3 times that for a new-generation non–drug-eluting stent (DES) and is not borne by a proportional increment in reimbursement. The average incremental reimbursement provided by the Center for Medicare and Medicaid Services for diagnosis-related group 527 (percutaneous cardiovascular procedure with DES, without acute myocardial infarction) is $1800 (geographically weighted). In societies in which patients are responsible for the large portion of cost increment related to a new technology, utilization of the Cypher stent has been limited. For example, 1 year after the release of Cypher in Europe (April 15, 2002), utilization remains ≤12% of all coronary stent devices. In the United States, we now find ourselves with an expensive new technology and a limited . . . [Full Text of this Article]

This article has been cited by other articles:

				I. J. Sarembock From Systemic Shotgun to Site-Specific Nanoparticle-Targeted Delivery: A New Paradigm for Drug Delivery Arterioscler Thromb Vasc Biol, November 1, 2008; 28(11): 1879 - 1881. [Full Text] [PDF]

				D. J. Kereiakes Does Clopidogrel Each Day Keep Stent Thrombosis Away? JAMA, January 10, 2007; 297(2): 209 - 211. [Full Text] [PDF]

				W. Yang, J. Ge, H. Liu, K. Zhao, X. Liu, X. Qu, W. Li, Y. Huang, A. Sun, and Y. Zou Arsenic trioxide eluting stent reduces neointima formation in a rabbit iliac artery injury model Cardiovasc Res, December 1, 2006; 72(3): 483 - 493. [Abstract] [Full Text] [PDF]

				S. Banai, S.D. Gertz, L. Gavish, M. Chorny, L. S. Perez, G. Lazarovichi, M. Ianculuvich, M. Hoffmann, M. Orlowski, G. Golomb, et al. Tyrphostin AGL-2043 eluting stent reduces neointima formation in porcine coronary arteries Cardiovasc Res, October 1, 2004; 64(1): 165 - 171. [Abstract] [Full Text] [PDF]

				D. J. Drenth, N. J.G.M. Veeger, J. G. Grandjean, M. A. Mariani, A. J. van Boven, and P. W. Boonstra Isolated high-grade lesion of the proximal LAD: a stent or off-pump LIMA? Eur. J. Cardiothorac. Surg., April 1, 2004; 25(4): 567 - 571. [Abstract] [Full Text] [PDF]

				D. P. Faxon Bringing Reality to Drug-Eluting Stents Circulation, January 20, 2004; 109(2): 140 - 142. [Full Text] [PDF]